Importantly, our validation using paired tumor and adjacent non-cancerous tissues confirmed this downregulation for ADARB2 but not for ADAR or ADARB1, suggesting that ADARB2 may represent the most robust biomarker candidate in this context. This evidence concerns the gene ADARB2 and neoplasm.